title: Hydration with 15 mEq Magnesium Is Effective at Reducingthe Risk for Cisplatin-induced Nephrotoxicity in Patients Receiving Cisplatin (≥50 mg/m2) Combination Chemotherapy.
abstract: OBJECTIVE
  We aimed to assess whether the efficacy of pre-hydration with 15 mEq magnesium prevents cisplatin-induced nephrotoxicity in cisplatin regimens (dosage: 50 mg/m(2)or more) for gynecological cancer.
  
  
  METHODS
  This historical, prospective cohort study compared nephrotoxicity in patients who received pre-hydration with or without magnesium sulfate (Mg-hydration group, n=37; non-Mg-hydration group, n=37). We used serum creatinine (Scr), creatinine clearance (Ccr) and Risk, Injury, Failure, Loss of kidney function and End-stage kidney disease (RIFLE) criteria.
  
  
  RESULTS
  A change of Scr and Ccr in the Mg-hydration group was higher than in the non-Mg-hydration group. Based on the RIFLE criteria, the number of moderate renal dysfunction patients classified as "Risk" in the Mg-hydration group was significantly lower than in the non-Mg-hydration group (Mg-hydration group=21.6%; non-Mg-hydration group=51.4%; p<0.01). Serum magnesium levels in the Mg-hydration group significantly declined during chemotherapy (p<0.01).
  
  
  CONCLUSIONS
  We found that a 15 mEq magnesium as pre-hydration provided nephroprotective effects in patients receiving this cisplatin regimen. Future research should involve finding appropriate magnesium doses.
authors.affiliation: Department of Pharmacy, Aichi Medical University School of Medicine, Aichi, Japan yamamo_0308@yahoo.co.jp.
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Yamamoto
authors.affiliation: Department of Obstetrics and Gynecology, Aichi Medical University School of Medicine, Aichi, Japan.
authors.forename: Kazushi
authors.initials: K
authors.lastname: Watanabe
authors.affiliation: Department of Pharmacy, Aichi Medical University School of Medicine, Aichi, Japan.
authors.forename: Ikuto
authors.initials: I
authors.lastname: Tsukiyama
authors.affiliation: Department of Obstetrics and Gynecology, Aichi Medical University School of Medicine, Aichi, Japan.
authors.forename: Hiromitsu
authors.initials: H
authors.lastname: Yabushita
authors.affiliation: Department of Pharmacy, Aichi Medical University School of Medicine, Aichi, Japan.
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Matsuura
authors.affiliation: Department of Obstetrics and Gynecology, Aichi Medical University School of Medicine, Aichi, Japan.
authors.forename: Akihiko
authors.initials: A
authors.lastname: Wakatsuki
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002945:Cisplatin / Q000009:adverse effects* / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy; D006801:Humans; D007674:Kidney Diseases / Q000097:blood / Q000139:chemically induced / Q000517:prevention & control*; D008278:Magnesium Sulfate / Q000097:blood / Q000627:therapeutic use*; D008875:Middle Aged; D019999:Pharmaceutical Solutions; D020011:Protective Agents / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D019999:Pharmaceutical Solutions; D020011:Protective Agents; D008278:Magnesium Sulfate; D003404:Creatinine; D002945:Cisplatin
keywords: Gynecological cancer; cisplatin; magnesium; nephrotoxicity; pre-hydration